Friday, 31 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Health and Wellness > FDA OK’s expansion of Novartis breast cancer therapy
Health and Wellness

FDA OK’s expansion of Novartis breast cancer therapy

Last updated: September 17, 2024 6:11 pm
Share
FDA OK’s expansion of Novartis breast cancer therapy
SHARE

Kisqali, a targeted therapy for breast cancer developed by Novartis, has received a significant approval from the Food and Drug Administration (FDA). Previously indicated only for patients with metastatic disease, Kisqali is now approved in combination with hormone therapy for patients with certain early-stage breast cancers. This expansion of approval will allow a larger number of patients to access this important drug.

Victor Bulto, president of Novartis United States unit, highlighted the significance of this approval, stating that it includes the entire stage 3 and 70% of stage 2 breast cancer patients. This approval sets Kisqali apart from other CDK4/6 inhibitors, as it now offers treatment to patients who do not have positive lymph nodes. CDK4/6 inhibitors like Kisqali target proteins that can enable cancer cells to grow uncontrollably, making them a key part of treatment for advanced hormone receptor positive, HER2 negative breast cancer.

The approval of Kisqali in early-stage breast cancer expands the options available to patients who may not have been considered candidates for other CDK4/6 inhibitors. Patients will receive Kisqali with endocrine therapy for three years after surgery to reduce the risk of recurrence. Data from Novartis’ Phase 3 NATALEE trial presented at the European Society of Medical Oncology meeting showed that Kisqali can reduce the risk of recurrence by 28.5% compared to endocrine therapy alone.

While Kisqali offers promising benefits, it does come with some side effects, including low white blood cell counts and joint pain. However, the benefits of treatment outweigh the risks for many patients. It is important to note that early detection of breast cancer is crucial, as cancers at earlier stages can often be effectively treated without the need for CDK4/6 inhibitors or chemotherapy.

See also  JUST IN: Joe Biden Breaks His Silence After Being Diagnosed with "Aggressive Form" of Prostate Cancer |

The approval of Kisqali for early-stage breast cancer marks a significant advancement in the treatment options available to patients. This new approval opens up the possibility of using CDK4/6 inhibitors in a broader group of patients, further improving outcomes and quality of life for those affected by breast cancer. Novartis continues to lead the way in developing innovative treatments for breast cancer, providing hope and progress for patients and healthcare providers alike.

TAGGED:breastcancerexpansionFDANovartisOKsTherapy
Share This Article
Twitter Email Copy Link Print
Previous Article Biden and Harris Accused of ‘Walking Tightrope’ Over Attacks on Trump Biden and Harris Accused of ‘Walking Tightrope’ Over Attacks on Trump
Next Article I Took The Henry Ford Professional Development Courses I Took The Henry Ford Professional Development Courses
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

RFK Jr., with Covid booster move, mounts an attack on health

Robert F. Kennedy Jr.’s recent decision to halt the Centers for Disease Control and Prevention's…

May 28, 2025

Rudy Giuliani’s Daughter Reveals What It’s Like Talking To Her Dad In Private

Caroline Rose Giuliani recently spoke out about her father, Rudy Giuliani, and the impact of…

October 7, 2024

Deal of the Day: Save 10% at Yankee Candle

Teachers, if you're looking to bring some calming aromas into your home, Yankee Candle has…

March 20, 2025

The Israeli Jews Who Spied For Iran In Biggest Infiltration In Decades

Tel Aviv: Israel recently apprehended nearly 30 individuals, mostly Jewish citizens, suspected of spying for…

December 11, 2024

Today’s top games to watch, best bets: Cardinals-Cubs, WNBA and more

The Chicago Cubs will take on the St. Louis Cardinals in a Sunday Night Baseball…

July 6, 2025

You Might Also Like

Cigna Profits Hit Nearly  Billion Despite Rising Costs
Health and Wellness

Cigna Profits Hit Nearly $2 Billion Despite Rising Costs

October 30, 2025
For cardiac health, exercise benefits women more than men
Health and Wellness

For cardiac health, exercise benefits women more than men

October 30, 2025
Hydrogen gas found to play key role in supporting gut health
Health and Wellness

Hydrogen gas found to play key role in supporting gut health

October 30, 2025
Alignment Healthcare Reports Second Profitable Quarter By Taming Costs
Health and Wellness

Alignment Healthcare Reports Second Profitable Quarter By Taming Costs

October 30, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?